OmniAb (OmniAb) Sale Of Investment : $122.80 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is OmniAb Sale Of Investment?

OmniAb's sale of investment for the three months ended in Mar. 2024 was $26.68 Mil. It means OmniAb gained $26.68 Mil from selling investments. OmniAb's sale of investment for the trailing twelve months (TTM) ended in Mar. 2024 was $122.80 Mil.

Compared with last quarter ($31.37 Mil in Dec. 2023 ), OmniAb gained less money from selling investments in Mar. 2024 ($26.68 Mil).

OmniAb Sale Of Investment Historical Data

The historical data trend for OmniAb's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OmniAb Sale Of Investment Chart

OmniAb Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Sale Of Investment

1.27

0.07

100.32

OmniAb Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Sale Of Investment	Get a 7-Day Free Trial									4.21	26.45	38.31	31.37	26.68

OmniAb Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $122.80 Mil.

OmniAb Sale Of Investment Related Terms

Thank you for viewing the detailed overview of OmniAb's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

OmniAb (OmniAb) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OmniAb Inc (NAS:OABI) » Definitions » Sale Of Investment

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608

Website

https://www.omniab.com

OmniAb Inc offers therapeutic antibody discovery technologies. Its focus is to enable the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully-human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Executives

Matthew W Foehr	director, officer: President & CEO	11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Steven Love	director	C/O OMNIAB, INC., 5980 HORTON STREET, SUITE 600, EMERYVILLE CA 94608
Carolyn R Bertozzi	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
John L Higgins	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Avista Capital Managing Member V, Llc	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V Gp, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners (offshore) V, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jennifer R. Cochran	director	C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Thompson Dean	director, 10 percent owner	65 EAST 55TH STREET, 18TH FLOOR, C/O AVISTA CAPITAL PARTNERS, NEW YORK NY 10022
Avista Acquisition Lp Ii	director, 10 percent owner	C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Acquisition Gp Llc Ii	director, 10 percent owner	C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
David F Burgstahler	director, 10 percent owner	C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Kurt A Gustafson	officer: EVP, Finance and CFO	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Sarah Boyce	director	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010